Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-hodgkin's lymphoma or multiple myeloma

Clinical Therapeutics

Volumn 32, Issue 5, 2010, Pages 821-843

  Steinberg, Michael ^a   Silva, Matthew ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

AMD3100; CXCR4; Hematopoietic stem cells; Lymphoma; Multiple myeloma; Plerixafor; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL DISTENSION; ANXIETY; APHERESIS; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOATING; CANCER CHEMOTHERAPY; CD34 SELECTION; CLINICAL TRIAL; CONSTIPATION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; EYE DISEASE; FATIGUE; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPESTHESIA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LACTATE DEHYDROGENASE BLOOD LEVEL; LOOSE FECES; MAGNESIUM BLOOD LEVEL; MALAISE; MENTAL DISEASE; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PARESTHESIA; SIDE EFFECT; STEM CELL MOBILIZATION; STOMACH DISCOMFORT; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; ECONOMICS, PHARMACEUTICAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; RECEPTORS, CXCR4;

EID: 77954804850     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.05.007     Document Type: Article

References (111)

1. Crawford S, Sullivan KM Bone marrow and stem cell transplantation and graft-versus-host-disease. Principles of Critical Care 2005, 1091-1102. McGraw-Hill, New York, NY. 3rd ed. J.B. Hall, G.A. Schmidt, L.D. Wood (Eds.).
2. Progress report January-December 2008, Center for International Blood & Marrow Transplant Research, Accessed April 7, 2010. http://www.cibmtr.org/About/AnnualReports/PDF/2008_CIBMTR_Annual_R.pdf.
3. Applebaum F Hematopoietic cell transplantation. Harrison's Principles of Internal Medicine 2008, 713-717. McGraw-Hill, New York, NY. 17th ed. A.S. Fauci, E. Braunwald, D.L. Kasper (Eds.).
4. Negrin RS, Blume KG Principles of hematopoietic cell transplantation. Williams Hematology 2006, 209-248. McGraw-Hill, New York, NY. 7th ed. M.A. Lichtman, E. Beutler, K. Kaushansky (Eds.).
5. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol. 1995, 13:1328-1335.
6. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients [published correction appears in Lancet. 1996;347:914]. Lancet 1996, 347:353-357.
7. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med. 1997, 126:600-607.
8. Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002, 29:967-972.
9. Villalón L, Odriozola J, Larana JG, et al. Autologous peripheral blood progenitor cell transplantation with <2 × 10(6) CD34(+)/kg: An analysis of variables concerning mobilisation and engraftment. Hematol J. 2000, 1:374-381.
10. Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007, 40:111-118.
11. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006, 37:719-724.
12. Jillella AP, Ustun C What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?. Stem Cells Dev. 2004, 13:598-606.
13. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000, 18:1360-1377.
14. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995, 85:588-596.
15. Stiff PJ Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant. 1999, 23(Suppl 2):S29-S33.
16. Sola C, Maroto P, Salazar R, et al. Bone marrow transplantation: Prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): The CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology. 1999, 4:195-209.
17. Duggan PR, Guo D, Luider J, et al. Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant. 2000, 26:1299-1304.
18. Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007, 40:437-441.
19. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995, 86:3961-3969.
20. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
21. Ikeda K, Kozuka T, Harada M Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci. 2004, 31:245-259.
22. Olavarria E, Kanfer EJ Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr Opin Hematol. 2000, 7:191-196.
23. Nervi B, Link DC, DiPersio JF Cytokines and hematopoietic stem cell mobilization. J Cell Biochem. 2006, 99:690-705.
24. DiPersio JF, Smith A, Sempek D, et al. Kinetics of autologous stem cell mobilization failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/ G-CSF, and chemotherapy/G-CSF on remobilization success. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 3380, Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/3380.
25. Mazumder A, Kaufman J, Lonial S, et al. Impact of prior lenalidomide treatment on peripheral blood stem cell (PBSC) mobilization in untreated multiple myeloma (MM) patients. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 3612, Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/3612.
26. Haas R, Möhle R, Frühauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994, 83:3787-3794.
27. Sugrue MW, Williams K, Pollock BH, et al. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2000, 39:509-519.
28. Fu P, Bagai RK, Meyerson H, et al. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant. 2006, 38:189-196.
29. Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998, 16:1547-1553.
30. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999, 17:3776-3785.
31. Mozobil (plerixafor injection) [prescribing information] 2008, Genzyme Corporation, Cambridge, Mass.
32. Bridger GJ, Skerlj RT, Thornton D, et al. Synthesis and structure-activity relationships of phenylenebis (methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication: Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem. 1995, 38:366-378.
33. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother. 1994, 38:668-674.
34. Morrison SJ, Uchida N, Weissman IL The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995, 11:35-71.
35. Jin F, Zhai Q, Qiu L, et al. Degradation of BM SDF-1 by MMP-9: The role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant. 2008, 42:581-588.
36. Uy GL, Rettig MP, Cashen AF Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008, 8:1797-1804.
37. Jin P, Wang E, Ren J, et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med. 2008, 6:39.
38. Cashen AF, Lazarus HM, Devine SM Mobilizing stem cells from normal donors: Is it possible to improve upon G-CSF?. Bone Marrow Transplant. 2007, 39:577-588.
39. Gupta SK, Pillarisetti K, Thomas RA, Aiyar N Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: Implications for development of selective CXCR4 antagonists. Immunol Lett. 2001, 78:29-34.
40. Wong RS, Bodart V, Metz M, et al. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol. 2008, 74:1485-1495.
41. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 [published correction appears in Nat Immunol. 2002;3:787]. Nat Immunol 2002, 3:687-694.
42. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002, 527:255-262.
43. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000, 44:1667-1673.
44. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacoki-netics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004, 37:1253-1262. AMD3100 HIV Study Group.
45. Lapidot T, Dar A, Kollet O How do stem cells find their way home?. Blood. 2005, 106:1901-1910.
46. Dar A, Kalinkovich A, Netzer N, et al. AMD3100 signals via the nervous system, inducing release to the circulation of bone marrow SDF-1, which is crucial for progenitor cell mobilization. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 1315, Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/1315.
47. Pulliam AC, Hobson MJ, Yang F, et al. AMD3100 and G-CSF synergize to promote repopulating stem cell mobilization in Fanca -/- and Fancc -/mice. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 3760, Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/3760.
48. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005, 201:1307-1318.
49. Hess DA, Bonde J, Craft TP, et al. Human CD34+ cells rapidly mobilized by AMD3100 repopulate NOD/ SCID mice with equivalent efficiency as CD34+ cells mobilized by G-CSF. Blood (ASH Annual Meeting Abstracts) 2004, 104. Abstract 1186.
50. Seeger T, Veldwijk M, Bridger G, et al. The CXCR4 antagonist AMD3100 mobilizes a more primitive subset of CD34+ cells than G-CSF. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 1969, Accessed July 10, 2009. http://www.abstracts.he-matologylibrary.org/cgi/content/abstract/106/11/1969.
51. Donahue RE, Jin P, Bonifacino AC, et al. AMD3100 and granulocyte colony stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and micro RNA expression. Blood (ASH Annual Meeting Abstracts) 2008, 112. Abstract 1385. Accessed July 10, 2009. http://www.abstracts.he-matologylibrary.org/cgi/content/abstract/112/11/1385.
52. Bonde J, Hess DA, DiPersio JF, et al. Multilineage analysis of paired AMD-3100 and G-CSF mobilized-peripheral blood stem cell products from healthy donors undergoing clinical mobilization: A pilot study. Blood (ASH Annual Meeting Abstracts) 2004, 104. Abstract 2848. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/104/11/2848.
53. Fruehauf S, Seeger T, Maier P, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol. 2006, 34:1052-1059.
54. Gai BQ, Holt MS, Nervi B, et al. Kinetics of hematopoietic progenitor cell mobilization with cyclophosphamide or cyclophosphamide plus AMD3100 using a mouse model. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 5217. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/5217.
55. Lack NA, Green B, Dale DC, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther. 2005, 77:427-436.
56. Cashen AF, Calandra G, MacFarland R, et al. A mobilizing regimen of AMD3100 and G-CSF increases stem cell collection in patients with Hodgkin's disease, and PK is similar to that of non-cancer patients. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 3053. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/3053.
57. MacFarland R, Ewesuedo RB, Badel K, Calandra G Pharmacokinetics of plerixafor (AMD3100) in volunteers with renal impairment. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 2878. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/2878.
58. Douglas S, Smith C, McFarland R, et al. AMD3100 with G-CSF for autologous peripheral blood progenitor cell (PBPC) mobilization in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM): Mobilization, engraftment, and pharmacokinetics (PK). Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 3383. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/3383.
59. Rettig MP, Ramirez P, Shannon WD, et al. Kinetics of stem cell and lymphoid subset mobilization in response to intravenous (IV) AMD3100 in mouse and man. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 1203. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/1203.
60. Marquez-Curtis LA, Montano J, Quinn D, et al. In vitro chemotactic index and response to CXCR4 antagonist AMD3100 correlate with CD34+ cell yield from leukapheresis products: Implications for poor mobilizers. Blood (ASH Annual Meeting Abstracts) 2006, 108. 60., Abstract 727. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/727.
61. Oelschlaegel U, Bornhaeuser M, Kroschinsky F, et al. Comparison of CXCR-4 and adhesion molecule expression in healthy bone marrow with expression in bone marrow and peripheral blood of patients receiving G-CSF plus AMD3100. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 1974. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/1974.
62. DiPersio J, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009, 113:5720-5726. 3102 Investigators.
63. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009, 27:4767-4773. 3101 Investigators.
64. Micallef IN, Apostolidis J, Rohatiner AZ, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J. 2000, 1:367-373.
65. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009, 15:249-256.
66. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008, 14:1253-1261.
67. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
68. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): An institutional experience. Bone Marrow Transplant. 2009, 43:909-917.
69. Tricot G, Cottler-Fox MH, Calandra G Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. 2010, 45:63-68.
70. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010, 45:39-47.
71. Ehninger G, Fruehauf S, Hubel K, et al. Steady state mobilization of autologous blood stem cells using G-CSF and AMD3100 in patients with multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 5219. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/5219.
72. Lemery SJ, Hsieh MM, Smith A, et al. A pilot study evaluating the CD34+ cell mobilizing activity and adverse events associated with escalating doses of AMD3100 in healthy volunteers. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 3278. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/3278.
73. Kalatskaya I, Berchiche YA, Gravel S, et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009, 75:1240-1247.
74. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Plerixafor plus G-CSF compared to chemotherapy plus G-CSF for mobilization of autologous CD34+ cells resulted in similar cost but more predictable days of apheresis and less hospitalization. Blood (ASH Annual Meeting Abstracts) 2009, 114. Abstract 2277. Accessed January 27, 2010. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/114/22/2277.
75. Alexander E, Costa LJ, Taylor M, et al. Cost-effective use of plerixafor for hematopoietic stem cells mobilization: Development and validation of a decision-making algorithm. Blood (ASH Annual Meeting Abstracts) 2009, 114. Abstract 3216. Accessed January 27, 2010. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/114/22/3216.
76. Redbook: Pharmacy's Fundamental Reference 2009, Thomson PDR, Montvale, NJ. 113th ed.
77. Takahashi Y, Chakrabarti S, Sriniivasan R, et al. A detailed phenotypic analysis using six color flow cytometry of lymphocyte subsets mobilized with AMD3100 compared to G-CSF. Blood (ASH Annual Meeting Abstracts) 2004, 104. Abstract 408. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/104/11/408.
78. Takahashi Y, Tawab A, Kurlander R, et al. AMD3100 mobilized apheresis products are rich in T-cells that do not undergo a Th-2 type cytokine polarization: Implications for allografting. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 296. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/296.
79. Colovai AI, Schwartz J, Slotky R, et al. Enhanced T cell function in patients with hematological malignancies undergoing mobilization for autologous stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 3288. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/3288.
80. Holtan SG, Porrata LF, Inwards DJ, et al. Effect of AMD3100 on T lymphocyte subpopulations in aphere-sis products of patients undergoing autologous hematopoietic stem cell transplantation for non Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 2918. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2918.
81. Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progressionfree survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007, 7:315-318.
82. Banchereau J, Steinman RM Dendritic cells and the control of immunity. Nature. 1998, 392:245-252.
83. Thomson AW, Turnquist HR, Zahorchak AF, Raimondi G Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance. Transplantation 2009, 87(Suppl 9):S86-S90.
84. Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocytecolony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev. 2007, 16:657-666.
85. Rettig MP, Ramirez P, Nervi B, DiPersio JF CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol. 2009, 460:57-90.
86. Devine SM, Vij R, Todt L, et al. HLA-matched sibling donor stem cell mobilization can be safely and effectively reduced from a five day to a one day process by a direct antagonist of the CXCR4/SDF-1 interaction. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 53. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/53.
87. Rettig M, Devine SM, Ritchey J, et al. Phenotypic and functional analysis of T-cells mobilized in HLA-matched sibling donors following treatment with the chemokine antagonist AMD3100. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 3001. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/3001.
88. Rettig M, Holt M, Liu F, et al. Evaluation of the phenotype and GVHD-inducing potential of splenic T cells isolated from G-CSF, AMD3100, or G-CSF and AMD3100 pretreated allogeneic donors. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 5224. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/5224.
89. Lundqvist A, Hamoui N, Andersson J, et al. Allograft cell content and GVHD differ in murine recipients of AMD3100 versus G-CSF mobilized peripheral blood stem cells. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 3108. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/3108.
90. Hess DA, Wirthlin L, Craft TP, et al. Human CD34+ cells mobilized by AMD3100 demonstrate enhanced NOD/SCID repopulating function compared to CD34+ cells mobilized by granulocyte colony stimulating factor. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 1962. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/1962.
91. Capoccia BJ, Shepherd RM, Guven H, et al. A comparison of the ability of AMD3100 versus G-CSF to induce angiogenesis and mobilize endothelial progenitor cells (EPCs). Blood (ASH Annual Meeting Abstracts) 2004, 104. Abstract 3597. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/104/11/3597.
92. Capoccia BJ, Shepherd RM, Link DC G-CSF and AMD3100 mobilize angiogenic cells into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 188. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/188.
93. Shepherd RM, Capoccia BJ, Devine SM, et al. AMD3100 and G-CSF mobilize angiogenic cells into the blood of healthy donors. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 3022. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/3022.
94. Balkwill F The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004, 14:171-179.
95. Balkwill F Cancer and the chemokine network. Nat Rev Cancer. 2004, 4:540-550.
96. Liesveld JL, Bechelli J, Rosell K, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 2007, 31:1553-1563.
97. Li JK, Yu L, Shen Y, et al. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol. 2008, 14:2308-2313.
98. Andreeff M, Konoplev S, Wang RY, et al. Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: First evidence in patients and potential for abolishing bone marrow microenvironmentmediated resistance. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 568. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/568.
99. Nervi B, Holt M, Rettig MP, et al. AMD3100 mobilizes acute promyelocytic leukemia cells from the bone marrow into the peripheral blood and sensitizes leukemia cells to chemotherapy. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 246. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/246.
100. Uy GL, Rettig MP, Ramirez P, et al. Kinetics of human and murine mobilization of acute myeloid leukemia in response to AMD3100. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 867. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/867.
101. Ramirez PA, Holt M, Rettig MP, et al. Mobilization of normal mouse progenitors and acute promyelocytic leukemia (APL) cells with inhibitors of CXCR4 and VLA-4 in splenectomized and unsplenectomized mice. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 2219. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/2219.
102. Liesveld JL, Lancet JE, Rosell KE, et al. The CXCR4 antagonist, AMD3100, inhibits AML transmi-gratory activity but does not alter blast proliferation or survival. Blood (ASH Annual Meeting Abstracts) 2004, 104. Abstract 2881. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/104/11/2881.
103. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009, 113:6206-6214.
104. Juarez J, Hewson J, Cisterne A, et al. CXCR4 antagonists mobilize acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment in mice. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 4592. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/4592.
105. Dillmann FM, Veldwijk MR, Calandra G, et al. AMD3100 inhibits chemotaxis towards SDF-1 and CXCR4-mediated stroma-contact in a dose-dependent manner, resulting in increased susceptibility to imatinib. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 4799. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/4799.
106. Ghobrial IM, Melhem M, Singha U, et al. The role of the CXCR4 inhibitor AMD3100 in multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 2492. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2492.
107. Runnels JM, Azab A, Pitsillides C, et al. In vivo mobilization of multiple myeloma cells out of the bone marrow using the CXCR4 inhibitor AMD3100 and bortezomib: Implications for sensitization of myeloma cells to apoptosis. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 2501. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/110/11/2501.
108. Velcade (bortezomib) [prescribing information] 2008, Millennium Pharmaceuticals, Inc, Cambridge, Mass.
109. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009, 113:4341-4351.
110. Ngo H, Hatjiharissi E, Leleu X, et al. The CXCR4/SDF-1 axis regulates migration and adhesion in waldenstrom macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 2418. Accessed July 10, 2009. http://www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/2418.
111. Uy GL, Goyal SD, Fisher NM, et al. Bortezomib administered pre-au-to-SCT and as maintenance therapy post transplant for multiple myeloma: A single institution phase II study. Bone Marrow Transplant. 2009, 43:793-800.